Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004584 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004584: Completed Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00004584 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004584, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor (a type of anti-HIV drug) called BMS-232632. Doctors will compare an anti-HIV drug combination that includes BMS-232632 to a drug combination that includes ritonavir.
Interventions
- DRUG Ritonavir
- DRUG Atazanavir
- DRUG Saquinavir
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-12 |
| Est. Completion | 2002-01 |
| Phase | Phase 2 |
What the finished NCT00004584 record still lists
NCT00004584 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which Ritonavir is the first listed.
NCT00004584 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004584 about?
NCT00004584 is a clinical study titled "Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment". The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor (a type of anti-HIV drug) called BMS-232632. Doctors will compare an anti-HIV drug combination that includes BMS-232632 to a drug combination that includes ritonavir.
What is the current status of trial NCT00004584?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-12. Estimated completion is 2002-01.
What interventions are being tested in trial NCT00004584?
The interventions under investigation include: Ritonavir (DRUG), Atazanavir (DRUG), Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00004584?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia